EFFECTS OF THE ADENOSINE A1-ANTAGONIST ROLOFYLLINE ON RENAL FUNCTION IN ACUTE HEART FAILURE PATIENTS: RESULTS FROM THE PROTECT STUDY  by Voors, Adriaan A. et al.
A33.E317
JACC March 9, 2010
Volume 55, issue 10A
 CARDIAC FUNCTION AND HEART FAILURE 
EFFECTS OF THE ADENOSINE A1-ANTAGONIST ROLOFYLLINE ON RENAL FUNCTION IN ACUTE HEART 
FAILURE PATIENTS: RESULTS FROM THE PROTECT STUDY
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Anemia and the Cardiorenal Syndrome
Abstract Category: Myocardial Function/Heart Failure--Clinical Pharmacological Treatment
Presentation Number: 1179-65
Authors: Adriaan A. Voors, Howard C. Dittrich, Barry M. Massie, Paul DeLucca, George Mansoor, Michael M. Givertz, PROTECT Investigators and 
Committees, Merck & Co., Inc., Rahway, NJ
Background: Small studies have indicated that adenosine A1 receptor antagonists enhance diuresis and may improve renal function in patients 
with chronic heart failure. We studied the effects of rolofylline on renal function in patients with acute heart failure (AHF) and renal dysfunction 
randomized in PROTECT, a pivotal phase III clinical trial.
Methods: A total of 2,033 patients with ADHF, volume overload, an estimated creatinine clearance (eCrCl; Cockcroft-Gault) between 20 and 80 ml/
min, and elevated natriuretic peptide levels were randomized within 24 hours of hospital admission in a 2:1 ratio to receive rolofylline 30 mg/day or 
placebo IV for up to 3 days. Renal function was measured daily up to 7 days and at day 14. Persistent worsening renal function (WRF) was defined 
as an increase in serum creatinine ≥ 0.3 mg/dL at both day 7 and 14, or initiation of dialysis or death by day 7.
Results: At baseline, mean (SD) eCrCl was 51.0 (20.5) ml/min in the placebo and 50.4 (20.0) ml/min in the rolofylline group. There was no 
difference in the change in creatinine or eCrCl between placebo- and rolofylline-treated patients during hospital admission or at day 14. After 4 days, 
mean body weight was reduced by 2.6 kg and 3.0 kg in the placebo and rolofylline treated patients, respectively (p=0.005). Persistent WRF occurred 
in 13.7% of the placebo group and 15.0% of the rolofylline group (OR (95% CI) vs. placebo: 1.11 (0.85, 1.46); p = 0.44). In multivariable analysis, 
adjusted for baseline variables, only the presence of anemia, but not use of placebo/rolofylline, was independently associated with persistent WRF. 
Persistent WRF was associated with an increased risk of death (HR 2.54; 95% CI 1.73-3.71) and death or cardiovascular or renal re-hospitalization 
through day 60 (HR 1.32; 95% CI 1.04-1.67).
Conclusions: In this large phase III clinical trial, the adenosine A1 receptor antagonist rolofylline did not prevent persistent WRF in AHF patients 
with volume overload and renal dysfunction. In the overall study, persistent WRF was independently associated with adverse clinical outcomes at 60 
days.
